On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...